EUCTR2004-004052-39-DKActive, not recruitingNot Applicable
Korttidsvækst hos børn med atopisk dermatitis behandlet med tacrolimus og hydrokortison-17-butyrat
BørneklinikkenRanders0 sites20 target enrollmentStarted: October 28, 2004Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •To assess skin prick test data, bone collagen turnover and an inflammation parameter in urine.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Pubertetsudvikling : Tanner stadie II - V.
- •Avendelse af enhver form for antiinflammatorisk behandling af atopisk dermatitis en uge inden visit 1 i periode 1.
- •Samtidig asthma bronchiale, og allergisk rhinoconjunktivitis, der kræver behandling med glukokortikoider
- •Endokrinologiske sygdomme – herunder vækstforstyrrelser – eller andre kroniske sygdomme.
- •Større operative indgreb 4 uger inden og under undersøgelsen.
- •Højfebril sygdom (t>39.5) af mere end 3 dages varighed.
Investigators
Similar Trials
Completed
Phase 4
Short Term Growth in Children With Atopic DermatitisAtopic DermatitisNCT00236106Children´s Clinic, Randers20
Completed
Not Applicable
nderstanding growth in patients with epidermolysis bullosa.Q81.2Q81.8Epidermolysis bullosa dystrophicaOther epidermolysis bullosaDRKS00013002Epidermolysis bullosa-Zentrum Freiburg, Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg - Eigenforschungsprojekt871
Terminated
Not Applicable
Research into the disease burden in patients with atopic eczemaAtopic dermatitisISRCTN84958399Pfizer (Netherlands)150
Active, not recruiting
Phase 3
Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT06701331AbbVie99
Completed
Not Applicable
Open labelled, single arm, interventional study of Apremilast in childhood dermatosisCTRI/2022/03/041201CUTIS Academy of Cutaneous Sciences15